サマリー

北米のガンマブチロラクトン市場は、2023年から2030年の予測期間に2.6%のCAGRを記録すると予測されます。この新しい市場レポートは、歴史的な年2021年のデータを含み、計算の基準年は2022年であり、予測期間は2023年から2030年です。

市場細分化：
北米のガンマブチロラクトン市場：グレード別（工業用クラス（5重量%）、電気容量クラス（9重量%）、一般クラス（8重量%））、純度（最低99.9%、最低99.7％）、用途（溶剤、鋳造用バインダー、除草剤・殺虫剤、電池・コンデンサ、塗料剥離剤、研磨剤、麻酔剤、鎮静剤、その他）、最終用途（医薬品業界、電機業界、農薬業界、石油業界、食品業界、その他）、国（U.S．国別（米国、カナダ、メキシコ）産業動向と2030年までの予測
北米のガンマブチロラクトン市場の成長に寄与する主な要因の一部をご紹介します：

- 半導体産業における溶剤としての応用
- 有機農薬の使用量増加

市場のプレーヤー：

北米のガンマブチロラクトン市場で活動している主なプレイヤーは以下の通りです：
- Zhejiang Realsun Chemical Co.Ltd.（浙江省）、Biosynth, Inc.
- バイオシンス
- BYNケミカル(株)
- BASF SE
- アシュランド
- 三菱化学株式会社
- バラジ・アミン

ページTOPに戻る

目次

TABLE OF CONTENTS
1 INTRODUCTION 21
1.1 OBJECTIVES OF THE STUDY 21
1.2 MARKET DEFINITION 21
1.3 OVERVIEW OF THE NORTH AMERICA GAMMA BUTYROLACTONE MARKET 21
1.4 LIMITATIONS 22
1.5 MARKETS COVERED 23
2 MARKET SEGMENTATION 26
2.1 MARKETS COVERED 26
2.2 GEOGRAPHICAL SCOPE 27
2.3 YEARS CONSIDERED FOR THE STUDY 28
2.4 CURRENCY AND PRICING 28
2.5 DBMR TRIPOD DATA VALIDATION MODEL 29
2.6 GRADE LIFE LINE CURVE 32
2.7 MULTIVARIATE MODELING 33
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 34
2.9 DBMR MARKET POSITION GRID 35
2.10 MARKET END-USE COVERAGE GRID 36
2.11 DBMR MARKET CHALLENGE MATRIX 37
2.12 DBMR VENDOR SHARE ANALYSIS 38
2.13 IMPORT-EXPORT DATA 39
2.14 SECONDARY SOURCES 40
2.15 ASSUMPTIONS 41
3 EXECUTIVE SUMMARY 42
4 PREMIUM INSIGHTS 44
4.1 PESTLE ANALYSIS 45
4.1.1 POLITICAL FACTORS 45
4.1.2 ECONOMIC FACTORS 46
4.1.3 SOCIAL FACTORS 46
4.1.4 TECHNOLOGICAL FACTORS 46
4.1.5 LEGAL FACTORS 46
4.1.6 ENVIRONMENTAL FACTORS 46
4.2 PORTER'S FIVE FORCES: 47
4.2.1 THREAT OF NEW ENTRANTS: 47
4.2.2 THREAT OF SUBSTITUTES: 47
4.2.3 CUSTOMER BARGAINING POWER: 48
4.2.4 SUPPLIER BARGAINING POWER: 48
4.2.5 INTERNAL COMPETITION (RIVALRY): 48
4.3 CLIMATE CHANGE SCENARIO 49
4.3.1 ENVIRONMENTAL CONCERNS 49
4.3.2 INDUSTRY RESPONSE 49
4.3.3 GOVERNMENT'S ROLE 49
4.3.4 ANALYST RECOMMENDATION 49
4.4 LIST OF KEY PATENTS LAUNCHED 50
4.5 SUPPLY CHAIN ANALYSIS 51
4.5.1 OVERVIEW 51
4.5.2 LOGISTIC COST SCENARIO 51
4.5.3 IMPORTANCE OF LOGISTICS SERVICE PROVIDERS 52
4.6 VENDOR SELECTION CRITERIA 53
5 MARKET OVERVIEW 54
5.1 DRIVERS 56
5.1.1 GROWING APPLICATION OF DERIVED CHEMICAL PRODUCTS 56
5.1.2 APPLICATION IN A WIDE RANGE OF INDUSTRIES 56
5.1.3 INCREASED DEMAND FOR ELECTRONIC ITEMS 57
5.2 RESTRAINTS 58
5.2.1 SERIOUS HEALTH EFFECTS AND SAFETY CONCERNS 58
5.2.2 STRINGENT RULES AND REGULATIONS 58
5.3 OPPORTUNITIES 59
5.3.1 RISE IN DEMAND FOR ELECTRIC VEHICLES 59
5.3.2 INCREASE IN USAGE OF ORGANIC AGROCHEMICALS 59
5.4 CHALLENGES 60
5.4.1 GOVERNMENT RESTRICTIONS FOR ILLEGAL USAGE 60
6 NORTH AMERICA GAMMA BUTYROLACTONE MARKET, BY GRADE 61
6.1 OVERVIEW 62
6.2 INDUSTRIAL CLASS (5 WT.%) 64
6.3 ELECTRIC CAPACITANCE CLASS (9 WT.%) 65
6.4 COMMON CLASS (8 WT.%) 66
7 NORTH AMERICA GAMMA BUTYROLACTONE MARKET, BY PURITY 67
7.1 OVERVIEW 68
7.2 MIN. 99.9% 69
7.3 MIN. 99.7% 70
8 NORTH AMERICA GAMMA BUTYROLACTONE MARKET, BY APPLICATION 71
8.1 OVERVIEW 72
8.2 SOLVENT 73
8.3 CASTING BINDER 74
8.4 HERBICIDES AND INSECTICIDES 74
8.5 BATTERIES AND CAPACITORS 75
8.6 PAINT STRIPPERS 76
8.7 POLISH REMOVERS 76
8.8 ANESTHETIC 77
8.9 SEDATIVE 78
8.10 OTHERS 79
9 NORTH AMERICA GAMMA BUTYROLACTONE MARKET, BY END-USE 80
9.1 OVERVIEW 81
9.2 PHARMACEUTICAL INDUSTRY 82
9.3 ELECTRICAL INDUSTRY 83
9.4 AGROCHEMICAL INDUSTRY 84
9.5 PETROLEUM INDUSTRY 84
9.6 FOOD INDUSTRY 85
9.7 OTHERS 86
10 NORTH AMERICA GAMMA BUTYROLACTONE MARKET, BY REGION 87
10.1 NORTH AMERICA 88
10.1.1 U.S. 93
10.1.2 CANADA 95
10.1.3 MEXICO 97
11 NORTH AMERICA GAMMA BUTYROLACTONE MARKET: COMPANY LANDSCAPE 99
11.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 99
11.2 RECOGNITION 100
11.3 AWARD 100
11.4 EVENT 101
11.5 EXPANSION 101
11.6 AGREEMENT 101
12 SWOT ANALYSIS 102
13 COMPANY PROFILES 103
13.1 MITSUBISHI CHEMICAL CORPORATION. 103
13.1.1 COMPANY SNAPSHOT 103
13.1.2 REVENUE ANALYSIS 103
13.1.3 COMPANY SHARE ANALYSIS 104
13.1.4 PRODUCT PORTFOLIO 104
13.1.5 RECENT DEVELOPMENTS 104
13.2 BASF SE 105
13.2.1 COMPANY SNAPSHOT 105
13.2.2 REVENUE ANALYSIS 105
13.2.3 COMPANY SHARE ANALYSIS 106
13.2.4 PRODUCT PORTFOLIO 106
13.2.5 RECENT DEVELOPMENT 106
13.3 SIPCHEM COMPANY 107
13.3.1 COMPANY SNAPSHOT 107
13.3.2 REVENUE ANALYSIS 107
13.3.3 COMPANY SHARE ANALYSIS 108
13.3.4 PRODUCT PORTFOLIO 108
13.3.5 RECENT DEVELOPMENTS 108
13.4 BALAJI AMINES 110
13.4.1 COMPANY SNAPSHOT 110
13.4.2 REVENUE ANALYSIS 110
13.4.3 COMPANY SHARE ANALYSIS 111
13.4.4 PRODUCT PORTFOLIO 111
13.4.5 RECENT DEVELOPMENTS 111
13.5 ASHLAND 112
13.5.1 COMPANY SNAPSHOT 112
13.5.2 REVENUE ANALYSIS 112
13.5.3 COMPANY SHARE ANALYSIS 113
13.5.4 PRODUCT PORTFOLIO 113
13.5.5 RECENT DEVELOPMENT 113
13.6 BIOSYNTH 114
13.6.1 COMPANY SNAPSHOT 114
13.6.2 PRODUCT PORTFOLIO 114
13.6.3 RECENT DEVELOPMENT 114
13.7 BOAI NKY PHARMACEUTICALS LTD. 115
13.7.1 COMPANY SNAPSHOT 115
13.7.2 PRODUCT PORTFOLIO 115
13.7.3 RECENT DEVELOPMENT 115
13.8 BYN CHEMICALS CO., LTD 116
13.8.1 COMPANY SNAPSHOT 116
13.8.2 PRODUCT PORTFOLIO 116
13.8.3 RECENT DEVELOPMENT 116
13.9 DCC 117
13.9.1 COMPANY SNAPSHOT 117
13.9.2 PRODUCT PORTFOLIO 117
13.9.3 RECENT DEVELOPMENT 118
13.10 ZHEJIANG REALSUN CHEMICAL CO.,LTD. 119
13.10.1 COMPANY SNAPSHOT 119
13.10.2 PRODUCT PORTFOLIO 119
13.10.3 RECENT DEVELOPMENTS 119
14 QUESTIONNAIRE 120
15 RELATED REPORTS 123

ページTOPに戻る

図表リスト

LIST OF TABLES
TABLE 1 IMPORT DATA OF LACTONES; HS CODE – 293220 (USD THOUSAND) 31
TABLE 2 EXPORT DATA OF LACTONES; HS CODE – 293220 (USD THOUSAND) 31
TABLE 3 NORTH AMERICA GAMMA BUTYROLACTONE MARKET, BY GRADE, 2017-2030 (USD THOUSAND) 55
TABLE 4 NORTH AMERICA GAMMA BUTYROLACTONE MARKET, BY GRADE, 2017-2030 (TONS) 55
TABLE 5 NORTH AMERICA INDUSTRIAL CLASS (5 WT.%) IN GAMMA BUTYROLACTONE MARKET, BY REGION, 2017-2030 (USD THOUSAND) 56
TABLE 6 NORTH AMERICA INDUSTRIAL CLASS (5 WT.%) IN GAMMA BUTYROLACTONE MARKET, BY REGION, 2017-2030 (TONS) 56
TABLE 7 NORTH AMERICA ELECTRIC CAPACITANCE CLASS (9 WT.%) IN GAMMA BUTYROLACTONE MARKET, BY REGION, 2017-2030 (USD THOUSAND) 57
TABLE 8 NORTH AMERICA ELECTRIC CAPACITANCE CLASS (9 WT.%) IN GAMMA BUTYROLACTONE MARKET, BY REGION, 2017-2030 (TONS) 57
TABLE 9 NORTH AMERICA COMMON CLASS (8 WT.%) IN GAMMA BUTYROLACTONE MARKET, BY REGION, 2017-2030 (USD THOUSAND) 58
TABLE 10 NORTH AMERICA COMMON CLASS (8 WT.%) IN GAMMA BUTYROLACTONE MARKET, BY REGION, 2017-2030 (TONS) 58
TABLE 11 NORTH AMERICA GAMMA BUTYROLACTONE MARKET, BY PURITY, 2017-2030 (USD THOUSAND) 61
TABLE 12 NORTH AMERICA MIN. 99.9% IN GAMMA BUTYROLACTONE MARKET, BY REGION, 2017-2030 (USD THOUSAND) 61
TABLE 13 NORTH AMERICA MIN. 99.7% IN GAMMA BUTYROLACTONE MARKET, BY REGION, 2017-2030 (USD THOUSAND) 62
TABLE 14 NORTH AMERICA GAMMA BUTYROLACTONE MARKET, BY APPLICATION, 2017-2030 (USD THOUSAND) 65
TABLE 15 NORTH AMERICA SOLVENT IN GAMMA BUTYROLACTONE MARKET, BY REGION, 2017-2030 (USD THOUSAND) 65
TABLE 16 NORTH AMERICA CASTING BINDER IN NORTH AMERICA GAMMA BUTYROLACTONE MARKET, BY REGION, 2017-2030 (USD THOUSAND) 66
TABLE 17 NORTH AMERICA HERBICIDES AND INSECTICIDES IN GAMMA BUTYROLACTONE MARKET, BY REGION, 2017-2030 (USD THOUSAND) 67
TABLE 18 NORTH AMERICA BATTERIES AND CAPACITORS IN GAMMA BUTYROLACTONE MARKET, BY REGION, 2017-2030 (USD THOUSAND) 67
TABLE 19 NORTH AMERICA PAINT STRIPPERS IN GAMMA BUTYROLACTONE MARKET, BY REGION, 2017-2030 (USD THOUSAND) 68
TABLE 20 NORTH AMERICA POLISH REMOVERS IN GAMMA BUTYROLACTONE MARKET, BY REGION, 2017-2030 (USD THOUSAND) 69
TABLE 21 NORTH AMERICA ANESTHETIC IN GAMMA BUTYROLACTONE MARKET, BY REGION, 2017-2030 (USD THOUSAND) 69
TABLE 22 NORTH AMERICA SEDATIVE IN GAMMA BUTYROLACTONE MARKET, BY REGION, 2017-2030 (USD THOUSAND) 70
TABLE 23 NORTH AMERICA OTHERS IN GAMMA BUTYROLACTONE MARKET, BY REGION, 2017-2030 (USD THOUSAND) 71
TABLE 24 NORTH AMERICA GAMMA BUTYROLACTONE MARKET, BY END-USE, 2017-2030 (USD THOUSAND) 74
TABLE 25 NORTH AMERICA PHARMACEUTICAL INDUSTRY IN NORTH AMERICA GAMMA BUTYROLACTONE MARKET, BY REGION, 2017-2030 (USD THOUSAND) 74
TABLE 26 NORTH AMERICA ELECTRICAL INDUSTRY IN GAMMA BUTYROLACTONE MARKET, BY REGION, 2017-2030 (USD THOUSAND) 75
TABLE 27 NORTH AMERICA AGROCHEMICAL INDUSTRY IN GAMMA BUTYROLACTONE MARKET, BY REGION, 2017-2030 (USD THOUSAND) 76
TABLE 28 NORTH AMERICA PETROLEUM INDUSTRY IN GAMMA BUTYROLACTONE MARKET, BY REGION, 2017-2030 (USD THOUSAND) 77
TABLE 29 NORTH AMERICA FOOD INDUSTRY IN GAMMA BUTYROLACTONE MARKET, BY REGION, 2017-2030 (USD THOUSAND) 77
TABLE 30 NORTH AMERICA OTHERS IN GAMMA BUTYROLACTONE MARKET, BY REGION, 2017-2030 (USD THOUSAND) 78
TABLE 31 NORTH AMERICA GAMMA BUTYROLACTONE MARKET, BY COUNTRY, 2017-2030 (USD THOUSAND) 83
TABLE 32 NORTH AMERICA GAMMA BUTYROLACTONE MARKET, BY COUNTRY, 2017-2030 (TONS) 83
TABLE 33 NORTH AMERICA GAMMA BUTYROLACTONE MARKET, BY GRADE, 2017-2030 (USD THOUSAND) 83
TABLE 34 NORTH AMERICA GAMMA BUTYROLACTONE MARKET, BY GRADE, 2017-2030 (TONS) 83
TABLE 35 NORTH AMERICA GAMMA BUTYROLACTONE MARKET, BY PURITY, 2017-2030 (USD THOUSAND) 84
TABLE 36 NORTH AMERICA GAMMA BUTYROLACTONE MARKET, BY APPLICATION, 2017-2030 (USD THOUSAND) 84
TABLE 37 NORTH AMERICA GAMMA BUTYROLACTONE MARKET, BY END-USE, 2017-2030 (USD THOUSAND) 84
TABLE 38 U.S. GAMMA BUTYROLACTONE MARKET, BY GRADE, 2017-2030 (USD THOUSAND) 85
TABLE 39 U.S. GAMMA BUTYROLACTONE MARKET, BY GRADE, 2017-2030 (TONS) 85
TABLE 40 U.S. GAMMA BUTYROLACTONE MARKET, BY PURITY, 2017-2030 (USD THOUSAND) 85
TABLE 41 U.S. GAMMA BUTYROLACTONE MARKET, BY APPLICATION, 2017-2030 (USD THOUSAND) 86
TABLE 42 U.S. GAMMA BUTYROLACTONE MARKET, BY END-USE, 2017-2030 (USD THOUSAND) 86
TABLE 43 CANADA GAMMA BUTYROLACTONE MARKET, BY GRADE, 2017-2030 (USD THOUSAND) 87
TABLE 44 CANADA GAMMA BUTYROLACTONE MARKET, BY GRADE, 2017-2030 (TONS) 87
TABLE 45 CANADA GAMMA BUTYROLACTONE MARKET, BY PURITY, 2017-2030 (USD THOUSAND) 87
TABLE 46 CANADA GAMMA BUTYROLACTONE MARKET, BY APPLICATION, 2017-2030 (USD THOUSAND) 88
TABLE 47 CANADA GAMMA BUTYROLACTONE MARKET, BY END-USE, 2017-2030 (USD THOUSAND) 88
TABLE 48 MEXICO GAMMA BUTYROLACTONE MARKET, BY GRADE, 2017-2030 (USD THOUSAND) 89
TABLE 49 MEXICO GAMMA BUTYROLACTONE MARKET, BY GRADE, 2017-2030 (TONS) 89
TABLE 50 MEXICO GAMMA BUTYROLACTONE MARKET, BY PURITY, 2017-2030 (USD THOUSAND) 89
TABLE 51 MEXICO GAMMA BUTYROLACTONE MARKET, BY APPLICATION, 2017-2030 (USD THOUSAND) 90
TABLE 52 MEXICO GAMMA BUTYROLACTONE MARKET, BY END-USE, 2017-2030 (USD THOUSAND) 90